Maximum Strength Acid Reducer Without prescription: NDMA impurity
Summary
See instructions below.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
Maximum Strength Acid Reducer Without prescription |
Maximum Strength Acid Reducer Without prescription |
DIN 02293471 |
Tablet |
Ranitidine (Ranitidine Hydrochloride) 150mg |
629744A, 629744B, 629744E, 629973C, 629973D, 632043A, 632043F, 632058B, 632058J, 629744F, 632058H, 629744G, 629973B, 632043D, 632043E, 632058A, 631893C, 629744H, 632058I, 629974A, 629974B, 629744I, 632043G, 632058D, 632058G, 629744J, 632043H, 629973A, 632043B, 629744C |
Issue
Presence of N-nitrosodimethylamine (NDMA) close or above the acceptable concentration limit in affected lots.
What you should do
- Talk to your doctor or pharmacist at your earliest convenience about alternative, non-ranitidine treatment options appropriate for your health circumstances. There are many prescription and over-the-counter drug alternatives in Canada that are authorized for the same or similar uses as ranitidine.
- Individuals taking a prescription ranitidine drug, including a recalled product, should not stop taking it unless they have spoken to their health care provider and obtained alternative treatment, as the risk of not treating the condition may be greater than the risk related to NDMA exposure.
- Contact your health care provider if you have taken a ranitidine product and you have concerns about your health.
- Report any health product adverse events or complaints to Health Canada.
Additional information
Previous recalls or alerts
Background
Depth of recall: Retailers
Details
Pharmascience Inc.
6111 ave. Royalmount,
Montreal, Quebec,
H4P 2T4
Get notified
Receive notifications for new and updated recalls and alerts by category.